Janux Therapeutics, Inc. $JANX is RA Capital Management L.P.'s 4th Largest Position

Key Points

• RA Capital Management L.P. increased its stake in Janux Therapeutics by 7.9%, owning approximately 11.2 million shares, which represents about 18.91% of the company.
• Several other hedge funds have also significantly increased their positions in Janux, indicating strong institutional interest, with hedge funds collectively owning 75.39% of the company's stock.
• Analysts have a consensus rating of "Buy" for Janux Therapeutics, with a target price of $86.90, reflecting optimism about the company's future growth potential.

RA Capital Management L.P. raised its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 7.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 11,189,693 shares of the company's stock after acquiring an additional 824,041 shares during the period. Janux Therapeutics makes up approximately 5.0% of RA Capital Management L.P.'s investment portfolio, making the stock its 4th largest position. RA Capital Management L.P. owned about 18.91% of Janux Therapeutics worth $302,122,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. GAMMA Investing LLC boosted its stake in Janux Therapeutics by 1,574.0% during the first quarter. GAMMA Investing LLC now owns 1,674 shares of the company's stock worth $45,000 after buying an additional 1,574 shares during the last quarter. US Bancorp DE grew its holdings in Janux Therapeutics by 2,402.9% in the 1st quarter. US Bancorp DE now owns 1,727 shares of the company's stock valued at $47,000 after buying an additional 1,658 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in Janux Therapeutics in the 4th quarter valued at $59,000. FNY Investment Advisers LLC grew its holdings in Janux Therapeutics by 6,928.6% in the 1st quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company's stock valued at $66,000 after buying an additional 2,425 shares in the last quarter. Finally, KBC Group NV purchased a new stake in Janux Therapeutics in the 1st quarter valued at $66,000. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on JANX shares. Piper Sandler started coverage on Janux Therapeutics in a report on Monday, August 18th. They issued an "overweight" rating and a $42.00 target price for the company. Guggenheim assumed coverage on Janux Therapeutics in a research report on Wednesday. They issued a "buy" rating and a $72.00 price objective for the company. Finally, Raymond James Financial assumed coverage on Janux Therapeutics in a research note on Friday, July 11th. They set an "outperform" rating and a $65.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, Janux Therapeutics currently has a consensus rating of "Buy" and an average target price of $85.55.

Janux Therapeutics Trading Up 0.2%

JANX stock traded up $0.04 during midday trading on Friday, hitting $23.98. 429,791 shares of the company's stock were exchanged, compared to its average volume of 663,439. The business has a 50-day simple moving average of $24.53 and a two-hundred day simple moving average of $26.61. The stock has a market capitalization of $1.44 billion, a PE ratio of -13.32 and a beta of 2.84. Janux Therapeutics, Inc. has a 1-year low of $21.97 and a 1-year high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.07). As a group, research analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.